Skip to Content
Merck
CN

Y0000297

Mesalazine

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

5-Aminosalicylic acid, 5-AS, 5-Amino-2-hydroxybenzoic acid, Mesalamine

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
H2NC6H3-2-(OH)CO2H
CAS Number:
89-57-6
Molecular Weight:
153.14
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329830901
MDL number:
MFCD00007877
Beilstein/REAXYS Number:
2090421

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Mesalazine, European Pharmacopoeia (EP) Reference Standard

storage temp.

2-8°C

InChI

1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)

SMILES string

Nc1ccc(O)c(c1)C(O)=O

InChI key

KBOPZPXVLCULAV-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

mesalamine, mesalazine

manufacturer/tradename

EDQM

mp

275-280 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... ALOX5(240), PPARG(5468), PTGS1(5742), PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

5-Aminosalicylic acid is a peroxidase substrate suitable for use in ELISA procedures. This substrate produces a soluble end product that is brown in color and can be read spectrophotometrically at 450 nm. The reaction may be stopped with 3 N NaOH and read at 550 nm.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

No data available

flash_point_c

No data available

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Marietta Iacucci et al.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 24(2), 127-133 (2010-02-13)
5-aminosalicylic acid (5-ASA) preparations (eg, mesalazine, mesalamine) are well-established preparations used in the management of inflammatory bowel disease. These drugs are most useful for the treatment of mild to moderate flares of ulcerative colitis and, especially, for maintenance of remission.
A H Steinhart et al.
Alimentary pharmacology & therapeutics, 25(12), 1389-1399 (2007-06-02)
To evaluate the effectiveness of pH 6-/pH 7-dependent and controlled-release mesalazines in maintaining medically and surgically induced Crohn's disease remission. A systematic search identified 13 randomized controlled trials (RCTs). The rate of symptomatic relapse (Crohn's disease activity index >150, or
Altamash I Qureshi et al.
Advanced drug delivery reviews, 57(2), 281-302 (2004-11-24)
Sulfasalazine's role as the first-line of therapy in patients with inflammatory bowel disease has led to the development of other "designer" aminosalicylates, which eliminate the sulfa-moiety, and attempt to target the topically active mesalamine to the inflamed bowel. Olsalazine sodium
P D R Higgins et al.
Alimentary pharmacology & therapeutics, 29(3), 247-257 (2008-10-24)
Ulcerative colitis (UC) can be maintained in remission with 5-aminosalicylic acid (5-ASA) medications, but frequent non-adherence by patients who are feeling well has been associated with more frequent flares of colitis. To perform a systematic review of the published literature
A M Schoepfer et al.
Alimentary pharmacology & therapeutics, 40(8), 930-937 (2014-08-26)
There is uncertain evidence of effectiveness of 5-aminosalicylates (5-ASA) to induce and maintain response and remission of active Crohn's disease (CD), and weak evidence to support their use in post-operative CD. To assess the frequency and determinants of 5-ASA use
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service